Ghent University Academic Bibliography

Advanced

The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments

Veerle Kersemans, Valentijn Vergote UGent, Virginie de Gelder UGent, Indira Madani UGent, Hubert Thierens UGent, Wilfried De Neve UGent, J MERTENS, Guido Slegers UGent, Christian Burvenich UGent and Kathelijne Peremans UGent, et al. (2008) CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 23(2). p.192-201
abstract
This study was performed to determine whether [ I-123]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase. Methods: In vitro, uptake of [I-125]-2-iodo-L-phenylalanine in RIM cells was tested after irradiation with Co-60 gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [I-123]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups. Results: The in vitro tests demonstrated that the [I-125]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [I-123]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the tumor-irradiated group, as compared to the contralateral-irradiated group and the not-irradiated control group. Conclusions: These findings in our cell and animal model systems indicate that [I-123]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
BIODISTRIBUTION, CARCINOMA, POTENTIAL TUMOR TRACER, RECURRENT BRAIN-TUMOR, RADIATION NECROSIS, SPECT, PET, THERAPY, DIAGNOSIS, POSITRON-EMISSION-TOMOGRAPHY, bystander effect, radiotherapy response, I-123]-2-iodo-L-phenylalanine, radiolabeled amino acids, tumor imaging
journal title
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Cancer Biother. Radiopharm.
volume
23
issue
2
pages
192-201 pages
Web of Science type
Article
Web of Science id
000255715100006
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
1.318 (2008)
JCR rank
63/90 (2008)
JCR quartile
3 (2008)
ISSN
1084-9785
DOI
10.1089/cbr.2007.0362
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
416532
handle
http://hdl.handle.net/1854/LU-416532
date created
2008-06-01 19:23:00
date last changed
2010-06-21 16:26:22
@article{416532,
  abstract     = {This study was performed to determine whether [ I-123]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase. Methods: In vitro, uptake of [I-125]-2-iodo-L-phenylalanine in RIM cells was tested after irradiation with Co-60 gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [I-123]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups. Results: The in vitro tests demonstrated that the [I-125]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [I-123]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the tumor-irradiated group, as compared to the contralateral-irradiated group and the not-irradiated control group. Conclusions: These findings in our cell and animal model systems indicate that [I-123]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy.},
  author       = {Kersemans, Veerle and Vergote, Valentijn and de Gelder, Virginie and Madani, Indira and Thierens, Hubert and De Neve, Wilfried and MERTENS, J and Slegers, Guido and Burvenich, Christian and Peremans, Kathelijne and De Spiegeleer, Bart},
  issn         = {1084-9785},
  journal      = {CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS},
  keyword      = {BIODISTRIBUTION,CARCINOMA,POTENTIAL TUMOR TRACER,RECURRENT BRAIN-TUMOR,RADIATION NECROSIS,SPECT,PET,THERAPY,DIAGNOSIS,POSITRON-EMISSION-TOMOGRAPHY,bystander effect,radiotherapy response,I-123]-2-iodo-L-phenylalanine,radiolabeled amino acids,tumor imaging},
  language     = {eng},
  number       = {2},
  pages        = {192--201},
  title        = {The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments},
  url          = {http://dx.doi.org/10.1089/cbr.2007.0362},
  volume       = {23},
  year         = {2008},
}

Chicago
Kersemans, Veerle, Valentijn Vergote, Virginie de Gelder, Indira Madani, Hubert Thierens, Wilfried De Neve, J MERTENS, et al. 2008. “The Use of [I-123]-2-iodo-L-phenylalanine as an Early Radiotherapy Evaluation Tool: In Vitro R1M Rabdomyosarcoma Cell and in Vivo Mouse Experiments.” Cancer Biotherapy and Radiopharmaceuticals 23 (2): 192–201.
APA
Kersemans, V., Vergote, V., de Gelder, V., Madani, I., Thierens, H., De Neve, W., MERTENS, J., et al. (2008). The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 23(2), 192–201.
Vancouver
1.
Kersemans V, Vergote V, de Gelder V, Madani I, Thierens H, De Neve W, et al. The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2008;23(2):192–201.
MLA
Kersemans, Veerle, Valentijn Vergote, Virginie de Gelder, et al. “The Use of [I-123]-2-iodo-L-phenylalanine as an Early Radiotherapy Evaluation Tool: In Vitro R1M Rabdomyosarcoma Cell and in Vivo Mouse Experiments.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 23.2 (2008): 192–201. Print.